2nd TRP Target Selection & Drug Design Summit, Feb 21-24, 2026 in Boston, US
[…]
PreTarg-it® - Fighting cancer with precision.
Pioneering game-changing radiopharmaceutical cancer therapies.
PreTarg-it® - Unlocking the Full Potential of Radioligand therapy
At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely while minimizing damage to healthy tissues.
PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy.
At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, combining the high precision of monoclonal antibodies and the power of radiotherapy to treat cancers more effectively.
PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy
At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely
Partnering & COLLABORATIONS
Partnering Oportunities
Partner with OncoOne to turn scientific insight into next-generation radioimmunotherapies.
OncoOne would like to explore strategic partnerships that would:
- Accelerate the clinical development of its pipeline in oncology and chronic inflammation.
- Leverage the existing expertise of its partner for selected disease areas and drug development.
OncoOne welcomes offers for:
- Global Licensing Transaction
- Strategic Alliance
- Build-to-Buy
OncoOne is open to:
- Investors for a Series A+/B financing enabling the company to take its first programs into the clinic.
- Discuss alternative investment approaches, including separate funding of its two platform technologies, Anti-oxMIF antibodies and PreTarg-it®
- Offers from Corporate Venture Funds for Early Stage strategic investment.
| Public Grants
